CRISPR Therapeutics AG
- Open
- 57.50
- Day high
- 57.69
- Day low
- 55.89
- Prev close
- 56.92
- Volume
- 73K
- Mkt cap
- $5.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.1
- P/S
- 407.7
- Yield
- —
- Per share
- —
CRISPR Therapeutics AG (CRSP) is a Healthcare company listed on NASDAQ. The stock is up 7% over the past year. Drillr has 2 published research articles covering CRSP.
CRISPR Therapeutics AG (CRSP) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CRSP earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $-1.19 | $-0.94 | +21.0% | $10M | +36.7% |
| May 4, 2026 | $-1.20 | $-1.28 | -6.6% | $1M | -76.0% |
| Feb 12, 2026 | $-1.15 | $-1.37 | -19.1% | $864000 | -81.7% |
| Feb 21, 2024 | $-0.07 | $1.10 | +1671.4% | $200M | +611.5% |
| Feb 21, 2023 | $-2.32 | $-1.41 | +39.2% | $6000 | -73.9% |
| Nov 1, 2022 | $-2.30 | $-2.24 | +2.6% | $94000 | -94.9% |
| Feb 15, 2022 | $-1.74 | $-1.84 | -5.7% | $12M | +465.0% |
| Nov 3, 2021 | $-1.69 | $-1.67 | +1.2% | $329000 | -60.5% |
| Jul 29, 2021 | $3.52 | $9.44 | +168.2% | $900M | +6.4% |
| Feb 16, 2021 | $-1.23 | $-1.50 | -22.0% | $194000 | -92.2% |
| Oct 28, 2020 | $-1.17 | $-1.32 | -12.8% | $148000 | +11.9% |
| Jul 27, 2020 | $-0.92 | $-1.30 | -41.3% | $44000 | +36.8% |
CRSP insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | High Katherine Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Greene Johndirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Rommel Christiandirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fardis Mariadirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Behbahani Alidirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Morrison Briggsdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | George Simeondirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Mahatme Sandeshdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Treco Douglas Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fleming Harold Edwarddirector | Grant | 13,000 | $51.84 |
| Jun 2, 2026 | Patel Naimishofficer: Chief Medical Officer | Grant | 22,000 | — |
| Jun 2, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Grant | 17,000 | — |
| Jun 2, 2026 | Prasad Rajuofficer: Chief Financial Officer | Grant | 19,500 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Option | 10,000 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Sell | 3,786 | $55.62 |
Source: CRSP SEC Form 4 filings, latest Jun 9, 2026. For informational purposes only — not investment advice.
See the full CRSP insider & 13F page →CRSP research & analysis
[VRTX] Vertex Thesis 2026: Alyftrek Transition + CASGEVY Scaling + Journavx Launch Test Diversification
Vertex Pharmaceuticals FY2025 revenue ~$12B (+9-12%) with adj. operating margin sustained at ~50%+. CF franchise (~$11B, 94% of revenue) at penetration ceiling — ~80%+ global CF patient share with Trikafta dominant. Alyftrek (next-gen vanzacaftor/tezacaftor/deutivacaftor, FDA approved Dec 2024) once-daily formulation transitioning Trikafta patients. CASGEVY (first CRISPR-based therapy approved, gene therapy for sickle cell + beta thalassemia) commercial ramp ~$200-400M FY2025 — slower than initial projections on operational complexity (~6-12 months patient process). Journavx (suzetrigine sodium channel blocker for acute pain, FDA approved Jan 2025) commercial launch ramping. FY2026 thesis: Alyftrek transition succeeds preserving CF franchise; CASGEVY scaling toward $1B+ as ATC capacity scales; Journavx capturing US acute pain share; pipeline (povetacicept IgA nephropathy + VX-880 type 1 diabetes) progressing.
VRTX[CRSP] CRISPR Therapeutics Thesis 2026: A CRISPR-Cas9 Gene-Editing Pioneer Scales Casgevy Royalty While Pipeline Validates In Vivo Applications
CRISPR Therapeutics AG (NASDAQ: CRSP), headquartered in Zug, Switzerland with operational headquarters in Cambridge, Massachusetts, is a clinical-and-commercial-stage biotech pioneering the development of CRISPR/Cas9-based gene-editing therapies for hematological diseases, oncology, autoimmune, cardiovascular, and regenerative-medicine indications. Founded in 2013 by Emmanuelle Charpentier (the 2020 Nobel Prize in Chemistry laureate for co-discovering CRISPR/Cas9 gene-editing with Jennifer Doudna — one of the most-significant biotechnology discoveries of the past 50 years) and co-founders with Versant Ventures as founding capital partner; IPO'd October 2016 at $14/share. Under President & CEO Sam Kulkarni (since 2022, joined CRISPR Therapeutics 2015, previously at Vertex), FY2025 closes with selected various aggregate revenue ~$50-150M (Casgevy commercial royalties + Vertex collaboration income), net loss ~$200-400M, cash + investments ~$1.6-1.9B (one of strongest cash positions in clinical-stage biotech relative to burn rate providing ~5+ year operating runway), and ~88M shares outstanding. The first deep-dive — the Casgevy commercial program + the Vertex Pharmaceuticals partnership — covers the first FDA-approved CRISPR/Cas9 gene-editing therapy. Casgevy (exagamglogene autotemcel, formerly exa-cel) approved by FDA December 2023 for sickle cell disease + January 2024 for transfusion-dependent beta-thalassemia — the first regulatory approval of a CRISPR/Cas9-based therapy anywhere in the world. Subsequent global approvals in EU, UK, Switzerland, Saudi Arabia, Bahrain through 2024-2025. The mechanism is a one-time autologous ex-vivo gene-editing therapy: collect patient HSCs via apheresis → edit ex-vivo using CRISPR/Cas9 to disable BCL11A (gene repressing fetal hemoglobin) → busulfan conditioning → re-infuse edited HSCs that engraft and express fetal hemoglobin compensating for defective adult hemoglobin. Patients are essentially cured. The Vertex Pharmaceuticals partnership is structurally central — Vertex handles commercial launch + marketing + distribution + manufacturing at Vertex cell-therapy facilities + regulatory/clinical-development; CRISPR Therapeutics receives mid-to-high-single-digit-to-low-double-digit royalty on worldwide Casgevy sales + collaboration revenue. Launch progressing modestly: ~50-200+ patients treated globally, ~75+ authorized treatment centers activated, $2.2M+ list price (one of highest in pharma history). Launch pace structurally slow due to procedure complexity + high price + addressable-population concentration + competitive alternative bluebird bio Lyfgenia for SCD. FY2026 catalyst is Casgevy commercial ramp pace, Vertex partnership execution, ATC activation, payer coverage, and indication expansion. The second deep-dive — the broader CAR-T cell therapy + cardiovascular gene-editing + autoimmune pipeline — covers CRSP's multi-program option-value-creating future-growth pillars. Allogeneic CAR-T cell therapies CTX112 (anti-CD19 for B-cell malignancies + autoimmune lupus/MG/MS) and CTX131 (anti-CD70 for solid tumors + heme malignancies) target the next-generation allogeneic CAR-T thesis — ready-to-use donor-derived CAR-T cells eliminating autologous manufacturing complexity + cost + logistics. The autoimmune-CAR-T category is one of the most exciting recent biotech areas with autologous CAR-T autoimmune-remission data showing dramatic clinical-response signals. In vivo cardiovascular gene editing — CTX320 (in vivo Lp(a) gene editing for cardiovascular risk reduction, ~$50B+ addressable market for Lp(a) lowering as independent CV/aortic-stenosis risk factor affecting ~20%+ of population) and CTX330 — represents the multi-billion-dollar in-vivo-cardiovascular-gene-editing thesis. FY2026 catalyst is CTX112 + CTX131 CAR-T clinical readouts, CTX320 Lp(a) Phase 1 data (dominant in-vivo platform validator), and platform-partnership announcements. Competes with Editas (EDIT), Beam (BEAM), Intellia (NTLA), Verve (VERV direct in-vivo CV comp), Prime Medicine (PRME), Sangamo (SGMO), Allogene (ALLO), Caribou (CRBU), Cellectis (CLLS); Lp(a) competitors Novartis Pelacarsen, Eli Lilly Muvalaplin, Amgen Olpasiran, Silence (SLN), Arrowhead (ARWR). Capital position is net-cash and growth-investment-focused: ~$1.6-1.9B cash (~5+ year runway), near-zero debt, negative FCF ~$200-400M/yr, R&D ~$300-500M/yr, SG&A ~$80-130M/yr, no dividend, modest opportunistic buybacks, SBC ~$80-120M/yr, ~88M shares. At ~$35-65 per share, equity value ~$3.5-6.0B and EV ~$1.7-4.2B (after ~$1.6-1.9B cash adjustment), valuation reflects option-value of diversified pipeline + Casgevy royalty NPV + net-cash cushion. Base case is Casgevy ramp + clinical readouts + moderate return; bull case is CTX320 Lp(a) Phase 1 delivery + CTX112 autoimmune validation + Casgevy acceleration + re-rating to $80-120+ + 50-100%+ return; bear case is pipeline misses + Casgevy stalls + runway concerns + de-rating to $20-30.
CRISPR Therapeutics AG company profile
Overview
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based gene editing company founded in 2013 that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform technology. The company went public in October 2016 and has emerged as one of the leading players in the rapidly evolving field of gene editing therapeutics. CRISPR Therapeutics focuses on creating treatments for conditions ranging from blood disorders to cancer and diabetes, with its lead therapy CTX001 representing one of the first CRISPR-based treatments to advance through clinical trials toward potential regulatory approval.
Business
CRISPR Therapeutics operates in the biotechnology sector, specifically in the gene editing space, where it develops therapeutic treatments by precisely modifying patients' genetic material to treat or cure diseases. The company's core technology platform is based on CRISPR/Cas9, which stands for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9. This technology functions like molecular scissors that can cut DNA at specific locations, allowing scientists to remove, add, or alter particular DNA sequences with unprecedented precision. The company's therapeutic pipeline spans multiple disease areas. CTX001 is the lead product candidate, an ex vivo gene-edited therapy designed to treat patients with transfusion-dependent beta-thalassemia and severe sickle cell disease. This treatment works by editing a patient's own hematopoietic stem cells (blood-forming cells) outside the body to produce high levels of fetal hemoglobin, which can compensate for defective adult hemoglobin in these inherited blood disorders. In oncology, CRISPR Therapeutics develops several allogeneic CAR-T therapies, which are cancer treatments using donor-derived immune cells that have been genetically modified to better attack cancer cells. These include CTX110 for blood cancers expressing CD19, CTX120 for multiple myeloma targeting BCMA, and CTX130 for various solid tumors and blood cancers targeting CD70. The advantage of allogeneic therapies is that they can be manufactured at scale from healthy donor cells, rather than requiring individual patient cell collection and modification. The company also pursues regenerative medicine through VCTX210, a gene-edited stem cell-derived therapy for type 1 diabetes, and various in vivo gene editing programs that target diseases in the liver, lung, muscle, and central nervous system by delivering gene editing tools directly into patients' bodies. Revenue generation is currently limited and primarily comes from strategic partnerships and collaboration agreements, with 2024 full-year revenue of $35 million compared to $371 million in 2023, indicating the lumpy nature of partnership milestone payments in the biotech industry.
Revenue model
CRISPR Therapeutics operates under a typical biotech business model where revenue generation occurs through multiple channels, though the company is still in the pre-commercialization phase for most of its pipeline. The primary revenue sources include strategic partnership agreements, milestone payments, research collaboration fees, and licensing arrangements with pharmaceutical companies like Vertex Pharmaceuticals, Bayer Healthcare, ViaCyte, Nkarta, and Capsida Biotherapeutics. The company's partnership with Vertex Pharmaceuticals for CTX001 represents a significant revenue opportunity, as Vertex handles much of the commercial development and the companies share costs and potential profits. When CTX001 and other therapies eventually reach market approval, CRISPR Therapeutics will generate revenue through product sales, royalties, and profit-sharing arrangements. Several factors significantly impact the company's financial performance and future profitability. Regulatory approval timelines represent the most critical factor, as delays in clinical trials or FDA/EMA approval processes directly affect when revenue generation can begin. Clinical trial success rates determine whether the substantial R&D investments will yield marketable products, with each failed program representing sunk costs. Manufacturing scalability and costs will heavily influence margins, particularly for complex cell therapies that require sophisticated production facilities and quality control measures. Competitive pressures from other gene editing companies, traditional pharmaceutical approaches, and emerging technologies could compress pricing power and market share. Intellectual property landscape affects both licensing costs and the ability to maintain competitive advantages. Healthcare reimbursement policies will determine market access and pricing for these expensive, cutting-edge therapies. Additionally, manufacturing capacity constraints and the specialized nature of gene editing therapies create both opportunities for premium pricing and risks of supply bottlenecks that could limit revenue growth even after successful product launches.
Competitive moat
CRISPR Therapeutics possesses several competitive advantages, though the durability of these moats faces significant challenges in the rapidly evolving gene editing landscape. The company's primary moat stems from its extensive intellectual property portfolio and early-mover advantage in CRISPR/Cas9 applications for therapeutic use. As one of the pioneering companies in the space, CRISPR Therapeutics has accumulated valuable clinical data, regulatory experience, and manufacturing know-how that creates barriers for later entrants. The company's strategic partnerships, particularly with Vertex Pharmaceuticals, provide significant competitive advantages through shared resources, reduced financial risk, and access to Vertex's commercial infrastructure and regulatory expertise. These partnerships also validate CRISPR's technology platform and provide credibility that can be difficult for smaller competitors to replicate. However, the company's moat faces substantial threats. The intellectual property landscape in gene editing remains highly contested, with ongoing patent disputes and the potential for competitors to develop alternative approaches that circumvent existing patents. Companies like Editas Medicine, Intellia Therapeutics, and Beam Therapeutics are pursuing similar or complementary gene editing technologies, while traditional pharmaceutical giants are either developing internal capabilities or acquiring gene editing companies. Technological disruption represents another significant risk, as newer gene editing technologies like base editing, prime editing, or entirely different approaches could potentially offer superior safety, efficacy, or cost profiles. The company's focus on ex vivo therapies, while currently advantageous, could become a limitation if in vivo delivery methods prove more commercially viable. The competitive moat is further challenged by the high capital requirements and regulatory expertise needed for gene editing therapies, which paradoxically both protect existing players and attract well-funded competitors. Large pharmaceutical companies with deeper pockets and broader pipelines may be able to sustain longer development timelines and absorb more failures than specialized biotech companies like CRISPR Therapeutics.
Risks & safety
CRISPR Therapeutics maintains a relatively strong financial position despite operating losses typical of pre-revenue biotech companies, though cash burn rates require careful monitoring. • Liquidity position: Strong current ratio of 22.1x with $298 million in cash and short-term investments as of Q4 2024, providing adequate runway for operations • Cash burn: Free cash flow negative $145 million for full year 2024, indicating approximately 2+ years of cash runway at current burn rates • Debt levels: Low debt-to-equity ratio of 0.12, minimal solvency risk with total liabilities of $310 million against $2.2 billion in total assets • Valuation metrics: Trading at 1.7x price-to-book ratio, which appears reasonable given the company's asset base and pipeline value • Operating losses: Net loss of $366 million in 2024, though this includes substantial R&D investments in pipeline development • Revenue volatility: Lumpy partnership revenue ($35M in 2024 vs $371M in 2023) creates forecasting challenges but reflects milestone-driven business model • Clinical risk: Pipeline success heavily dependent on regulatory approvals and clinical trial outcomes, with binary risk/reward profile typical of biotech investments
Recent development
Based on the financial data trends, CRISPR Therapeutics has been navigating the typical biotech development cycle with significant R&D investments and partnership-driven revenue fluctuations. The company's revenue dropped dramatically from $371 million in 2023 to $35 million in 2024, reflecting the milestone-based nature of biotech partnerships where large payments are received when specific development or regulatory milestones are achieved. The company has maintained substantial cash reserves while continuing to invest heavily in clinical development, with operating cash flow losses of $143 million in 2024 compared to $260 million in 2023, suggesting some improvement in cash management efficiency. The consistent current ratios above 15x indicate strong liquidity management and the ability to fund operations through multiple development cycles. Recent strategic developments appear focused on advancing the clinical pipeline, particularly the lead program CTX001 in partnership with Vertex Pharmaceuticals. The company's asset base has remained relatively stable around $2.2-2.3 billion, suggesting continued investment in manufacturing capabilities, clinical infrastructure, and intellectual property development. The partnership strategy continues to be central to CRISPR's development approach, providing both financial support and risk-sharing for expensive clinical programs. The company's ability to maintain strong balance sheet metrics while pursuing multiple therapeutic programs simultaneously indicates disciplined capital allocation and successful partnership structuring that reduces individual program risk exposure.
CRSP company profile · for informational purposes only — not investment advice.
Track CRSP with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free